Mohammad A Nezami

Making the Case for MTET (eBook, ePUB)

Where Miracles Become Standard In Oncology

• Format: ePub

Produktbeschreibung

Millions of cancer cases are diagnosed yearly. While a cure has yet to be discovered, one of the most promising new treatments is Multi-Targeted Epigenetic Therapy, or MTET.

In Making the Case for MTET, world-renowned oncology expert Dr. Mohammad A. Nezami introduces his revolutionary method of treating patients with advanced cancer by using a careful combination of drugs and genomic sequencing. For some patients with stage four cancer, MTET has been a lifesaving intervention.

Dr. Nezami presents 300 case studies of patients with advanced cancer that he treated over ten years of longitudinal tracking with MTET. Through meticulously documented data, lab reports, and full-color photographs to detailed genomic information, Dr. Nezami makes a compelling case for furthering MTET research and focusing on patient-centric care.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.

Produktdetails

• Verlag: Cancer Research and Life Foundation
• Seitenzahl: 574
• Erscheinungstermin: 1. März 2024
• Englisch
• ISBN-13: 9798989395200
• Artikelnr.: 70089197

Autorenporträt

Mohammad A. Nezami, MD, author of Transition from Crime to Care in Oncology: A Critical Review of Current Cancer Research and Its Applications, is a world-renowned authority on integrative oncology and epigenetic sciences and a graduate of the University of Southern California and University of California San Francisco residencies. He serves as the president of Medical Centers of Hope in California. He has contributed to numerous medical publications and has made presentations to such organizations as the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Dr. Nezami, who currently teaches and consults other physicians and oncologists, is extensively involved in research and pursuing several clinical trials in integrative oncology and epigenetic sciences.